Drug trial aims to calm deadly COVID-19 immune storm
NCT ID NCT04412772
Summary
This study tested whether a drug called tocilizumab could help adults hospitalized with severe COVID-19 pneumonia. The goal was to see if the drug, which calms an overactive immune system, could improve patients' health status and reduce the need for breathing support compared to a placebo. The trial was stopped early and only enrolled 20 of a planned 300 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Queen's Medical Center
Honolulu, Hawaii, 96813, United States
Conditions
Explore the condition pages connected to this study.